

RISANKIZUMAB solution for injection (Skyrizi® ▼) for plaque psoriasis

The Pan Mersey Area Prescribing Committee recommends the prescribing of RISANKIZUMAB solution for injection (Skyrizi® ▼), by specialists only, for moderate to severe plaque psoriasis in accordance with NICE TA596.

RED

Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.¹

NICE technology appraisal (TA) 596² recommends risankizumab solution for injection (Skyrizi® ▼) as an option for treating plaque psoriasis in adults, only if:

- > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10, **and**
- > the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated, **and**
- > the company provides the drug according to the commercial arrangement.

Stop risankizumab treatment at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as:

- > a 75% reduction in the PASI score (PASI 75) from when treatment started, **or**
- > a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started.

If patients and their clinicians consider risankizumab to be one of a range of suitable treatments, including guselkumab, secukinumab and ixekizumab, the least expensive should be chosen (taking into account administration costs, dosage, price per dose and commercial arrangements).

Prescribing and monitoring of therapy must be retained by a specialist in the management of psoriasis.

NICE do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,000 per 100,000 population). This is because risankizumab is a further treatment option and is available at a similar price to existing options.

References

1. AbbVie Ltd. Summary of Product Characteristics. [Skyrizi 75 mg solution for injection in pre-filled syringe](#), 18 July 2019. Accessed online 22 August 2019.
2. National Institute for Health and Care Excellence. [Risankizumab for treating moderate to severe plaque psoriasis](#) NICE Technology Appraisal 596, 21 August 2019. Accessed online 22 August 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.